title: Sildenafil and retinopathy of prematurity
text: |
  Sildenafil and retinopathy of prematurity
  |
  bet | 558/654 | Sana | 03.01.2022 | Hajmi | 1,5 Mb. | | #14803 |
  Sildenafil and retinopathy of prematurity
  Sildenafil is 10 x more selective for PDE5 as compared to PDE6. PDE6 is found in the retina. If used in extremely preterm neonates, sildenafil may increase the risk of severe retinopathy of prematurity. A retrospective, case-controlled study (n = 68) in neonates born before 30 weeks gestation showed sildenafil use did not increase the risk of retinopathy of prematurity.3
  References
  |
  1. Barst RJ, Ivy DD, Gaitan G, Szatmari A, Rudzinski A, Garcia AE, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation. 2012;125(2):324-34.
  2. Barst RJ, Beghetti M, Pulido T, Layton G, Konourina I, Zhang M, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension. Circulation 2014;129(19):1914-23.
  3. Fang AY, Guy KJ, König K. The effect of sildenafil on retinopathy of prematurity in very preterm infants. J Perinatol. 2013 Mar;33(3):218-21.
  4. Hansmann G, Apitz C. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016;102 Suppl 2:ii67-85.
  5. Hilgendorff A, Apitz C, Bonnet D, Hansmann G. Pulmonary hypertension associated with acute or chronic lung diseases in the preterm and term neonate and infant. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016;102 Suppl 2ii49-56.
  6. König K, Barfield CP, Guy KJ, Drew SM, Andersen CC. The effect of sildenafil on evolving bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled pilot study. J Matern Fetal Neonatal Med. 2014;27(5):439-44.
  7. Kozlik-Feldmann R, Hansmann G, Bonnet D, Schranz D, Apitz C, Michel-Behnke I. Pulmonary hypertension in children with congenital heart disease (PAH-CHD, PPHVD-CHD). Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 2016;102 Suppl 2ii42-8.
  8. Namachivayam P, Theilen U, Butt WW, Cooper SM, Penny DJ, Shekerdemian LS. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 2006;174(9):1042-7.
  9. Shah PS, Ohlsson A. Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev. 2011 Aug 10;(8):CD005494.
  10. Steinhorn RH, Kinsella JP, Pierce C, Butrous G, Dilleen M, Oakes M, Wessel DL. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr 2009 Dec;155(6):841-847.e1.
  11. Stocker C, Penny DJ, Brizard CP, Cochrane AD, Soto R, Shekerdemian LS. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med. 2003;29(11):1996-2003.
  12. Vassalos A, Peng E, Young D, Walker S, Pollock J, Macarthur K, Lyall F, Danton MH. Pre-operative sildenafil and pulmonary endothelial-related complications following cardiopulmonary bypass: a randomised trial in children undergoing cardiac surgery. Anaesthesia 2011;66(6):472-80.
  13. Dhariwal AK, Bavdekar SB. Sildenafil in pediatric pulmonary arterial hypertension. J Postgrad Med. 2015 Jul-Sep;61(3):181-92.
  14. Roldan T, Deiros L, Romero JA, Gutierrez-Larraya F, Herrero A, Del Cerro MJ. Safety and tolerability of targeted therapies for pulmonary hypertension in children. Pediatric cardiology. 2014 Mar 1;35(3):490-8.
  |
  |
  | |